WILEX AG successfully completes rights issue

ENGLISH DEUTSCH
PDF Download
back

Munich, Germany, 11 May 2017 – The Executive Management Board of WILEX AG (ISIN DE000A11QVV0 and DE000A2E4SX4) today decided – with the Supervisory Board’s approval – to set the final scope of the rights issue to be executed to a total of 2,040,816 new shares.

WILEX’s shareholders exercised their subscription and additional subscription rights for 2,040,816 new no par value bearer shares at a price of EUR 2.45 per share by the end of the subscription period on 10 May 2017. Thereby, shareholders exercised subscription rights for a total of 1,257,632 new shares. This meant that 783,184 new shares were available for additional subscription by shareholders, which have been fully placed to the shareholders through the custodian banks in connection with the capital increase. The Company’s main shareholder – dievini Hopp BioTech holding GmbH & Co. KG, Walldorf – exercised all of its subscription rights and subscribed to more shares under additional subscription.

Dr Jan Schmidt-Brand commented: “This rights issue is one step to execute the EUR 10 million commitment from our main shareholder, dievini, made earlier this year. With the funds raised in this capital increase, we are able to continue critical work to advance our lead product candidate, HDP-101. We are grateful to our shareholders for their support and trust.”

The rights offering will increase the Company’s share capital by EUR 2,040,816.00, from EUR 12,927,564.00 to EUR 14,968,380.00, once it has been entered in the Commercial Register.

WILEX AG plans to use the expected gross proceeds from the rights issue of almost EUR 5.0 million mainly to finance the preclinical development of its proprietary ATAC candidate HDP-101 and to establish the GMP manufacturing process for Antibody Targeted Amanitin Conjugates (ATACs).

The subscribed and allotted shares are expected to be delivered on 18 May 2017, but no earlier than after their admission to trading on the Regulated Market (Prime Standard). The new shares are due to be included in trading on 18 May 2017. All new shares carry dividend rights from 1 December 2016. Given this difference in dividend rights, the new shares will be traded separately under the ISIN DE000A2E4SX4 / WKN A2E 4SX until the planned inclusion in the Company’s current listing, which will take place after the Annual General Meeting (expected on 20 July 2017) adopting resolutions regarding the 2015/2016 financial year. Baader Bank AG, Unterschleissheim was the sole lead manager of the capital increase.

About WILEX
WILEX AG is a biopharmaceutical company based in Munich, Germany, that serves as a parent and holding company. The Company’s research and development work is conducted by its subsidiary Heidelberg Pharma GmbH in Ladenburg. Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the company’s own therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA-ATAC for multiple myeloma. WILEX’s clinical assets MESUPRON® and REDECTANE® have been partnered, while RENCAREX® is available for out-licensing and further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / Symbol WL6. More information is available at www.wilex.com.

Contact
WILEX AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 (0)89-41 31 38-29
Email: investors[at]wilex.com
Grillparzerstr. 18, 81675 Munich
IR/PR support
MC Services AG

Katja Arnold (CIRO)
Executive Director & Partner
Tel.: +49-89-210 228-40
E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will”, “should”, “future”, “potential” or similar expressions or by a general discussion of the Company’s strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial position, earnings, achievements, or industry results, to be materially different from any future results, earnings or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Seite gelesen: 2975 | Heute: 3